Fig. 1. The anti-tumour activity of MI-773 in the 274-CL panel in vitro.

a The individual dose–response curves of all CLs to MI-773. Each line corresponds to a fitted displacement curve for a CL. x-axis, MI-773 concentration in µM. Y-axis, drug effects on cell proliferation and survival expressed as Test/Control × 100 (%) values. b Rank ordered Abs IC₅₀ values obtained for each CL. The dashed red line depicts the median Abs IC₅₀ value. Dashed black lines are the cut-offs of 1 and 10 µM identifying highly sensitive (<1 µM), intermediate sensitive ([1, 10 [µM) and resistant (≥10 µM) CLs. c Scatter plot of the drug potency expressed with Abs IC₅₀ value per CL (x-axis). On the y-axis, the histological (sub)types are sorted from top to bottom by increasing median Abs IC₅₀ values. Between brackets the total number of CLs within a tumour (sub)type. Abbreviations: CNS_GBM central nervous system: glioblastoma, CRC colorectal cancer, HNSC head &neck squamous cell, LE_ALL acute lymphoblastic leukaemia, LE_AML acute myeloid leukaemia, LE_CLL chronic lymphocytic leukaemia, LE_CML chronic myelogenous leukaemia, Liver_chol Liver_cholangioma, Liver_hep liver_hepatocellular, LY_Burkitt lymphoma_Burkitt, LY_DLBC lymphoma_Diffuse large B cells, LY_Hodgkin lymphoma_Hodgkin, LY_MM lymphoma_multiple myeloma, LY_unclass lymphoma_unclassified, NSCL_ad non-small cell lung_adenocarcinoma, NSCL_ep non-small cell lung_epidermoid, NSCL_large non-small cell lung_large cells, NSCL_unclass non-small cell lung_unclassified, SA_Ewing Sarcoma Ewing, SA_osteo osteosarcoma, SA_soft t sarcoma soft tissue, SCLC small cell lung, uterus_endo uterus_endometrium. d The percentage of highly sensitive (light blue), intermediate sensitive (grey-blue) and resistant CLs (dark blue) to MI-773 across different tumour types.